Background Women with estrogen deficiencies can suffer from vaginal symptoms that negatively impact sexual health. This study evaluated vaginal dehydroepiandrosterone (DHEA) for alleviation of vaginal symptoms. Methods This three-arm randomized, controlled trial evaluated DHEA 3.25 mg and DHEA 6.5 mg, each compared to a plain moisturizer (PM) over 12 weeks, to improve the severity of vaginal dryness or dyspareunia, measured with an ordinal scale, and overall sexual health using the Female Sexual Function Index (FSFI). Postmenopausal women with a history of breast or gynecologic cancer who had completed primary treatment, had no evidence of disease, and reported at least moderate vaginal symptoms were eligible. The mean change from baseline to week 12 in the severity of vaginal dryness or dyspareunia for each DHEA dose was compared to PM and analyzed by two independent t tests using a Bonferroni correction. Results Four hundred sixty-four women were randomized. All arms reported improvement in either dryness or dyspareunia. Neither DHEA dose was statistically significantly different from PM at 12 weeks (6.25 mg, p = .08; 3.25 mg, p = 0.48), although a significant difference at 8 weeks for 6.5 mg DHEA was observed (p = 0.005). Women on the 6.5 mg arm of DHEA reported significantly better sexual health on the FSFI (p < 0.001). There were no significant differences in provider-graded toxicities and few significant differences in self-reported side effects. Conclusion PM and DHEA improved vaginal symptoms at 12 weeks. However, vaginal DHEA, 6.5 mg, significantly improved sexual health. Vaginal DHEA warrants further investigation in women with a history of cancer.
Background Prevalence and significance
Sexual health is considered a major survivorship issue worthy of attention that, to date, is not well addressed in cancer care [1] [2] [3] . Women diagnosed with breast or gynecologic cancer can experience a decline in sexual health soon after diagnosis [4] [5] [6] [7] which may persist or worsen over 5 years [5] . The prevalence of sexual health issues has been estimated to be 30 to 100% [6, 7] .
One of the most consistently identified predictors of impaired sexual health in women is the presence of vaginal symptoms [8] [9] [10] [11] [12] . The vagina is highly regulated by estrogen; therefore, cancer treatment that results in estrogen depletion causes unwanted effects on the vagina resulting in vaginal dryness and discomfort, pain and bleeding associated with intercourse, and increased susceptibility to infections, all of which may impair enjoyment of sexual intimacy [13] .
Standard/current treatment
The gold standard treatment for vaginal symptoms is low dose vaginal estrogen [14, 15] (e.g., 7.5 micrograms [mcg] suppository) to provide symptom relief while minimizing systemic effects, but use in the breast oncology community is controversial, particularly for women on aromatase inhibitors (AI). A small group of retrospective studies have not demonstrated increased rates of breast cancer recurrence with the use of vaginal estrogens or oral estrogen therapy [16] [17] [18] , but definitive safety studies are not currently available.
Recent ASCO/ACS survivorship guidelines and the North American Menopause Society recommend the use of nonhormonal treatments, specifically water-or silicone-based lubricants and vaginal moisturizers as first line treatment [15, 19] . Lubricants are used at the time of sexual activity. Vaginal moisturizers, involving bases such as polycarbophil, hyaluronic acid, gums, or gelatins, may be used on a regular basis for hydrating vaginal tissue. Moisturizers have been shown to improve symptoms and pH, but have not been shown to improve tissue health, specifically cell maturation [14] .
Localized dehydroepiandrosterone (DHEA) has been evaluated as a treatment for vaginal dryness and dyspareunia and has demonstrated efficacy [20] [21] [22] [23] . A DHEA containing ovule has just been FDA approved for moderate to severe dyspareunia in postmenopausal women. DHEA is produced primarily by the adrenal gland and serves as a precursor to estrogen and androgen production. It has low androgenic potency. Previous work with DHEA has reported that, when administered vaginally, it is converted into active forms of estrogen and/or testosterone on intracellular receptors, providing local activity [20, 22] .
Vaginal DHEA has not been studied in women with a history of cancer, and given the extreme estrogen deprivation women on aromatase inhibitors experience, it is not possible to generalize results from studies in women with natural or surgically induced menopause to cancer survivors, particularly those on AI's. Therefore, in this study, we sought to evaluate two low doses of vaginal DHEA 3.25 and 6.5 mg, to minimize the amount of drug exposure, for the symptoms of vaginal dryness or dyspareunia in female cancer survivors.
Methods Eligibility
Women eligible for this study included those who were postmenopausal, with a history of breast or gynecologic cancer and no current evidence of disease who had completed chemotherapy and radiation. Women had to report either dyspareunia or vaginal dryness of at least moderate severity, and this symptom had to have been present for at least 2 months.
Women could be on tamoxifen or an AI for at least 8 weeks, without plans to change treatment during the study. Participants could not use vaginal products other than waterbased lubricants during intercourse. Women were not eligible for the study if they had prior pelvic surgery resulting in anatomical changes, had prior radiation to the pelvis, active vaginal infections, or had used any hormonal product (including soy or any compounded hormones) in the preceding 4 weeks.
Randomization
In this three-arm randomized controlled trial, women were randomized to receive either DHEA 3.25 mg or DHEA 6.5 mg in a bioadhesive moisturizer base or a plain bioadhesive moisturizer alone (PM). Both investigators and patients were blinded to t reatment assignment . Randomization was accomplished using the Pocock-Simon dynamic allocation procedure that balances the marginal distributions of the stratification factors between the treatment groups [24] . Women were stratified by hysterectomy status (yes or no), cigarette smoking history (current, past, or never), use of AIs (anastrozole/letrozole, exemestane or none), and the current use of tamoxifen (yes or no).
Measures
The primary aim of this study was to compare DHEA 3.25 mg versus PM and DHEA 6.5 mg versus PM over 12 weeks for the alleviation of the most bothersome vaginal symptom. The primary endpoint was measured with an ordinal scale, where women rated severity of their most bothersome symptom, either dryness or dyspareunia, as none, mild, moderate, severe, or very severe. The choice of this primary outcome was influenced by two factors; this was the outcome used in the previous DHEA trial whose product is now FDA approved [21] and both symptoms are well established sequelae of the effects of estrogen deprivation on the vagina [13, 15, 25] . The primary outcome measure was administered at baseline and at weeks 2, 4, 8, and 12.
Secondary outcomes included side effects as measured by provider-reported Common Terminology Criteria of Adverse Events (CTCAE) v4.0 and an investigator-developed self-report questionnaire which asks participants to report on 8 potential toxicities and overall quality of life (QOL), using a numeric analog scale from 0 ("not at all") to 10 ("as bad as it can be") [26] . For the analysis, these numbers were inverted such that negative numbers indicate worsening of symptoms and positive numbers indicate improvement. Side effects were measured at baseline and weeks 2, 4, 8, and 12.
An important secondary outcome was overall sexual function, measured by the Female Sexual Function Index (FSFI) [27] . The FSFI is a relatively brief multi-dimensional measure of 19 items that addresses the major domains of female sexual functioning, including desire, arousal, lubrication, orgasm, satisfaction, and pain. The FSFI has been validated for use in adult women, including cancer survivors [28] , with the most recent Cronbach alphas being over 0.9 for internal reliability. A score of 26 is reported to be the cut point to distinguish women with and without sexual dysfunction (lower scores indicating sexual dysfunction) [29] , other dysfunction scores are ≤ 3 in the pain subscale and ≤ 4.35 for the lubrication subscale [29] . The FSFI was completed at baseline and 12 weeks. Several physiologic endpoints were evaluated, including hormone concentrations and biomarkers of bone turnover, and are to be published separately.
Intervention and control
Vaginal DHEA was developed by a compounding pharmacist located in North Dakota. An IND, # 111454, was obtained. The base of the compound, developed specifically for this study to be bioadhesive, included carbomer, squalane, vitamin E acetate USP liquid, distilled water, methylparaben NF powder, propylparaben NF powder, glycerin, and zinc acetate and was used as the plain moisturizer for the control arm of this study. The DHEA was added to result in either 3.25 mg/ 0.4 mL or 6.5 mg/0.4 mL gel. Small syringes without a needle, used as applicators, were prefilled with DHEA or plain moisturizer gel. All study syringes were identical in all respects so the assigned treatment was blinded. Study participants were instructed to insert one syringe of gel daily right before going to bed, after any sexual activity, in a ribbon like fashion, withdrawing the syringe slowly as they pushed the plunger to apply the gel. Women were asked to do this every night for 12 weeks.
Statistical analysis
Sample size was determined to balance the need for an appropriate effect size and results that were clinically meaningful [30] . An effect size of 0.36 SD was selected *p=0.005; 6.5 mg DHEA vs. PM **p=0.08; 6.5 mg DHEA vs. PM Fig. 2 Mean change in severity of dryness or dyspareunia over 12 weeks for this trial to provide clinical relevancy and based on previous work by Labrie [21, 23] . Using a Bonferroni correction due to having two correlated primary hypothesis tests, [31] 3.25 mg DHEA vs plain moisturizer and 6.5 mg DHEA vs plain moisturizer, 145 patients per group were required to provide 80% power to detect a difference of 0.36 SD with a type I error of 2.5%.
The primary analysis considered the endpoint as continuous in nature and used the mean change from baseline to week 12 in the woman's most bothersome symptom, either dryness or dyspareunia. Two independent paired t tests were utilized. The study results were confirmed using logistic regression when considering the endpoint as ordinal in nature and using the last value carried forward missing data imputation method. Finally, subset analyses were performed to look at potential AI effects on outcomes.
Summary statistics including means and frequencies were calculated, and endpoints analyzed with the appropriate statistical methods including Chi-square tests, Fisher-exact tests, and t tests.
This study was monitored by the NCCTG External Data Monitoring Committee (DMC), a National Cancer Instituteapproved body, and registered NCT01376349. Reports containing efficacy, adverse event, and administrative information were provided to the DMC every 6 months per NCI guidelines. Each participant signed an IRB-approved informed consent in accordance with federal and institutional guidelines.
Data collection and statistical analyses were conducted by the Alliance Statistics and Data Center (SDC). Data quality was ensured by review of data by the Alliance SDC and by the study chairperson (DLB) following Alliance policies. Analyses were based on the study database frozen on July 15, 2013.
Results

Accrual and demographics
The CONSORT diagram is shown in Fig. 1 . Eighty-two institutions across the USA and Canada enrolled 464 women between July, 2011 and April, 2013; 147-149 women were randomized to each arm. Attrition rates were 18% leaving 112-123 per arm with primary endpoint data. Baseline characteristics of the women in the study (Table 1) were not significantly different between arms. At baseline, the percentage of women reporting dryness as their most bothersome symptom was 49% in the PM group, 40% in the 3.25 mg DHEA arm, and 42% in the 6.5 mg DHEA group while those reporting dyspareunia as the most bothersome symptom were 51% in the PM group, 60% in the 3.25 mg DHEA group, and 58% in the 6.5 mg DHEA arm. The mean severity of the most bothersome symptom (dryness or dyspareunia) was rated as 4 for women in each DHEA arm and 4.1 for women in the PM group (out of a possible 5) indicating that it was severe. 
Primary outcome
The change from baseline to week 12 for the most bothersome symptom decreased for all arms as follows: PM: − 1. Fig. 2 . At week 8, there was a statistically significant decrease in the most bothersome symptom for women in the 6.5 mg vaginal DHEA arm compared to those in the PM arm (p = 0.005), but this did not remain statistically significant at 12 weeks.
Secondary outcomes
There were no statistically significant differences between groups in any grade toxicity as graded by the CTCAE version 4.0 (data not shown). The most common clinician graded CTCAE side effects (> 5%) included headache and breast pain, which were not different between arms. Hirsutism and specific components of hirsutism (voice alteration, increased body hair, and acne) were graded by providers primarily as grade 1 (98%), and again, there were no significant differences between arms.
Self-reported side effect changes during the study are listed in Table 2 . Small, but statistically significant, differences occurred in women receiving DHEA compared with PM, with worsening voice changes reported among women in the 3.25 and 6.5 mg DHEA arms, and headaches in the 3.25 mg DHEA arm compared to PM.
Mean values and change from baseline for the FSFI subscales of arousal, lubrication, satisfaction, and pain as well as the total score (overall sexual function) for the FSFI and overall QOL are shown in Table 3 . Overall sexual function and QOL improved significantly in the 6.5 mg DHEA group compared to the PM group (p ≤ 0.01 for both FSFI total score and QOL). In addition, women receiving DHEA 6.5 mg reported significant improvements in all subscales of the FSFI (arousal, lubrication, pain, and satisfaction) with the exception of orgasm, compared to PM, while women receiving 3.25 mg of DHEA reported significant improvements on arousal and pain subscales compared to those receiving the PM.
Use of an AI, versus not, did not lead to any difference in the primary (most bothersome symptom of dryness or dyspareunia) or secondary (FSFI subscales or total score) outcomes. Within those women receiving DHEA, the change in severity for the most bothersome symptom at 12 weeks was − 1.7 (CI: − 1.91, − 1.48) for those on an AI (N = 126), and − 1.6 (CI: − 1.85, − 1.40) for those not on an AI (N = 116) (p = 0.76). Similar benefits were demonstrated on the FSFI, the total score change at 12 weeks was 6.5 for women on an AI and 6.1 for women not on an AI (p = 0.47).
In an exploratory manner, the severity of vaginal dryness and dyspareunia were analyzed separately. Patients scored the 
Discussion
The data from this randomized clinical trial demonstrates that over 12 weeks, a vaginal bioadhesive moisturizer and DHEA both improve the severity of vaginal symptoms of pain or dryness. DHEA 6.5 mg, however, improved symptoms more quickly, with a significant difference at 8 weeks. In addition, only women in the DHEA arms reported significant improvement on the sexual health measure. Thus, this study provides partial support and some consistency with previously published data on vaginal DHEA [21, 23] . Specifically, the data from this study demonstrates improved sexual function, as measured by the FSFI, with the use of DHEA. In fact, per well-established cut points for the pain subscale of the FSFI, as reported in Table 2 , only women receiving DHEA reported post-treatment mean scores in the normal range (≥ 3) [29] . Further research could identify those women whose symptoms are not adequately managed with a plain bioadhesive moisturizer, who might benefit from DHEA. It may seem surprising that a bioadhesive moisturizer over a 12-week period improved vaginal symptoms of dryness and dyspareunia. Current recommendations for the use of a moisturizer are 3 to 5 days per week. In our study, women used the moisturizer every night for 12 weeks. It may be that increased frequency is necessary for women with more moderate to severe vaginal symptoms to experience symptom improvement. This study provides data that supports that the use of a moisturizer over 12 weeks, used before bed after any sexual activity, was able to improve vaginal symptoms, no matter whether it was dryness or dyspareunia. We hypothesize that nightly application of the moisturizer was important to allow tissue hydration.
Based on the two self-reported side effects (voice change and headaches) that were statistically significantly worse than the plain moisturizer, it is important to note that some women may experience androgen-related side effects on DHEA. As in all treatment for symptoms, individual risk/benefit should be evaluated. Physiologic endpoints for this study, including androgen concentrations, will be reported separately.
Recently, additional treatments have been found to be helpful in alleviating vaginal symptoms. One oral option, Ospemifene, is a Food and Drug Administration-approved selective estrogen receptor modifier (SERM) for moderate to severe dyspareunia in postmenopausal women. As a systemically active agent, this drug is associated with potential adverse effects including hot flashes and venous thromboembolic events [15] and has not been studied in women with breast or gynecologic malignancies. Another treatment, topical 4% lidocaine, was recently shown to improve pain and/or tenderness in the vulvar vestibule [32] . This small study recruited women shown to positively respond to topical lidocaine, and then evaluated the treatment in a randomized, blinded trial. Therefore, this treatment option is specific to vulvar issues and is not likely to improve more general symptoms in the vaginal vault.
In summary, daily use of a vaginal moisturizer has the ability to improve vaginal symptoms over 12 weeks but may not sufficiently positively impact overall sexual function. For that reason, the role of vaginal DHEA requires further research in women with a history of cancer.
